Most clinicians caring for NAFLD patients routinely obtain ALT to assess change over time; however, the literature has mixed support for this approach and it is uncertain whether ALT is valid for measuring change in inflammation and liver damage. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.